Literature DB >> 12363035

Cyclin A in cell cycle control and cancer.

C H Yam1, T K Fung, R Y C Poon.   

Abstract

Cyclin A is particularly interesting among the cyclin family because it can activate two different cyclin-dependent kinases (CDKs) and functions in both S phase and mitosis. An embryonic form of cyclin A that is only essential for spermatogenesis is also present in some organisms. In S phase, phosphorylation of components of the DNA replication machinery such as CDC6 by cyclin A-CDK is believed to be important for initiation of DNA replication and to restrict the initiation to only once per cell cycle. In mitosis, the precise role of cyclin A is still obscure, but it may contribute to the control of cyclin B stability. Cyclin A starts to accumulate during S phase and is abruptly destroyed before metaphase. The synthesis of cyclin A is mainly controlled at the transcription level, involving E2F and other transcription factors. Removal of cyclin A is carried out by ubiquitin-mediated proteolysis, but whether the same anaphase-promoting complex/cyclosome targeting subunits are used as for cyclin B is debatable. Consistent with its role as a key cell cycle regulator, expression of cyclin A is found to be elevated in a variety of tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12363035     DOI: 10.1007/s00018-002-8510-y

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  178 in total

Review 1.  Posttranscriptional regulation of cancer traits by HuR.

Authors:  Kotb Abdelmohsen; Myriam Gorospe
Journal:  Wiley Interdiscip Rev RNA       Date:  2010-05-06       Impact factor: 9.957

Review 2.  Function of the A-type cyclins during gametogenesis and early embryogenesis.

Authors:  Debra J Wolgemuth
Journal:  Results Probl Cell Differ       Date:  2011

Review 3.  Ubiquitin, the centrosome, and chromosome segregation.

Authors:  Ying Zhang; Paul J Galardy
Journal:  Chromosome Res       Date:  2016-01       Impact factor: 5.239

4.  Novel Survivin Inhibitor for Suppressing Pancreatic Cancer Cells Growth via Downregulating Sp1 and Sp3 Transcription Factors.

Authors:  Myrna Hurtado; Umesh T Sankpal; Aboubacar Kaba; Shahela Mahammad; Jaya Chhabra; Deondra T Brown; Raj K Gurung; Alvin A Holder; Jamboor K Vishwanatha; Riyaz Basha
Journal:  Cell Physiol Biochem       Date:  2018-11-30

5.  IFI27, a novel epidermal growth factor-stabilized protein, is functionally involved in proliferation and cell cycling of human epidermal keratinocytes.

Authors:  W-L Hsieh; Y-H Huang; T-M Wang; Y-C Ming; C-N Tsai; J-H S Pang
Journal:  Cell Prolif       Date:  2015-02-09       Impact factor: 6.831

6.  Upregulated microRNA-224 promotes ovarian cancer cell proliferation by targeting KLLN.

Authors:  Ke Hu; Meng Liang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-09-23       Impact factor: 2.416

7.  DNA damage during the spindle-assembly checkpoint degrades CDC25A, inhibits cyclin-CDC2 complexes, and reverses cells to interphase.

Authors:  Jeremy P H Chow; Wai Yi Siu; Tsz Kan Fung; Wan Mui Chan; Anita Lau; Talha Arooz; Chuen-Pei Ng; Katsumi Yamashita; Randy Y C Poon
Journal:  Mol Biol Cell       Date:  2003-07-25       Impact factor: 4.138

8.  Expression of the p12 subunit of human DNA polymerase δ (Pol δ), CDK inhibitor p21(WAF1), Cdt1, cyclin A, PCNA and Ki-67 in relation to DNA replication in individual cells.

Authors:  Hong Zhao; Sufang Zhang; Dazhong Xu; Marietta Ywt Lee; Zhongtao Zhang; Ernest Yc Lee; Zbigniew Darzynkiewicz
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 9.  Sirtuins-Mediated System-Level Regulation of Mammalian Tissues at the Interface between Metabolism and Cell Cycle: A Systematic Review.

Authors:  Parcival Maissan; Eva J Mooij; Matteo Barberis
Journal:  Biology (Basel)       Date:  2021-03-04

10.  Loss of Cdk2 and cyclin A2 impairs cell proliferation and tumorigenesis.

Authors:  Lakshmi Gopinathan; Shawn Lu Wen Tan; V C Padmakumar; Vincenzo Coppola; Lino Tessarollo; Philipp Kaldis
Journal:  Cancer Res       Date:  2014-05-06       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.